M&A

News

Biogen bets $1.15bn on immunology drug developer HI-Bio

Biogen has expanded its specialty immunology pipeline with an agreement to buy Human Immunology Biosciences (HI-Bio) and its lead drug felzartamab, in trials for a range o

News

Merck builds in cell, gene therapies with Mirus Bio deal

Germany’s Merck KGaA has agreed to acquire Mirus Bio, a specialist in transfection reagents used in the production of cell and gene therapies (CGTs), in a deal valued at a

News

Click buys Better assets to speed its digital obesity drive

Click Therapeutics has snapped up the assets of troubled digital health company Better Therapeutics, including its FDA-approved prescription digital therapeutic (PDT) for

News

J&J reels in bispecific specialist Proteologix in $850m deal

Johnson & Johnson has agreed a $850 million deal to acquire Proteologix that will give it a pair of early-stage bispecific antibodies with immunology applications, inc

News

Mariana Oncology's chief executive Simon Read

Novartis digs deeper in radiopharma with $1.75bn Mariana buy

Novartis has struck another deal to strengthen its position in radiopharmaceuticals, agreeing to pay $1 billion upfront for radioligand therapy (RLT) developer Mariana Onc

News

Ono swoops on Deciphera in $2.4 billion takeover

Japan’s Ono Pharma has bolstered its cancer pipeline with a $2.4 billion agreement to buy Deciphera Pharma of the US and its fast-growing gastrointestinal stromal tumour (

Biogen bets $1.15bn on immunology drug developer HI-Bio

Merck builds in cell, gene therapies with Mirus Bio deal

Click buys Better assets to speed its digital obesity drive

J&J reels in bispecific specialist Proteologix in $850m deal

Novartis digs deeper in radiopharma with $1.75bn Mariana buy

Ono swoops on Deciphera in $2.4 billion takeover

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

M&A

Editor's Picks